Skip to main content

Table 1 Description of the sample

From: Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer’s disease (DELCODE)

  CO (n = 141) SCD (n = 126) MCI (n = 65) AD (n = 40) Relatives of AD patients (n = 22) F value/χ2 value
Age (years), mean (SD) 68.6 (5.1) 71.4 (5.7)*** 72.8 (5.2)*** 72.8 (7.1)** 64.8 (4.5)** 15.4, p > 0.001
Sex (female), n (%) 83 (58.9) 65 (51.6) 25 (38.5)** 23 (57.5) 12 (54.5) 7.9, n.s.
Education (years), mean (SD) 15.0 (2,7) 14.7 (3.1) 14.1 (3.1) 13.2 (3.2)** 13.7 (2.6)* 3.78, p = 0.005
MMSE, mean (SD) 29.4 (0.9) 29.1 (1.0) 28.0 (1.6)*** 23.6 (3.3)*** 29.0 (1.2) 135, p < 0.001
CDR, mean (SD) 0.0 (0.0) 0.2 (0.2)*** 0.5 (0.1)*** 0.8 (0.2)*** 0.1 (0.2) 216, p < 0.001
CDR-SOB, mean (SD) 0.0 (0.1) 0.4 (0.4)*** 1.6 (1.2)*** 4.7 (1.3)*** 0.4 (1.0) 343, p < 0.001
ADAScog 13, mean (SD) 5.6 (3.3) 7.0 (3.9)** 15.3 (6.3)*** 29.1 (8.1)*** 8.0 (5.2) 220, p < 0.001
FAQ, mean (SD) 0.1 (0.4) 0.8 (1.2)*** 3.5 (4.4)*** 11.8 (6.2)*** 0.4 (1.0) 154, p < 0.001
GDS, mean (SD) 0.7 (1.4) 1.9 (1.7)*** 1.8 (1.6)*** 2.1 (1.5)*** 1.1 (1.3) 12.5, p < 0.001
APOE genotype (n = 131) (n = 114) (n = 60) (n = 36) (n = 19)  
 APOE4 genotype of all APOE, n (%) 23 (17.6) 37 (32.5)** 22 (36.7)** 25 (69.4)*** 8 (42.1)* 37.3, p < 0.001
CSF biomarkers (n = 50) (n = 45) (n = 35) (n = 18) (n = 6)  
 Aβ42 (pg/ml), mean (SD) 890 (323) 748 (329)* 630*** (303) 353 (100)*** 684 (415) 11.1, p < 0.001)
 Aβ42 < 496 pg/ml, n (%) 5 (10.0) 9 (20.0) 16 (45.7)*** 18 (100)*** 2 (33.3) 54.9, p < 0.001
 Aβ42/Aβ40, mean (SD) 0.099 (0.022) 0.093 (0.026) 0.077 (0.031)** 0.046 (0.015)*** 0.077 (0.036) 16.0, p < 0.001
 Aβ42/Aβ40 < 0.09, n (%) 14 (28.0) 17 (37.8) 21 (60.0)** 17 (94.4)*** 4 (66.7) 28.3, p < 0.001
 tTau (pg/ml), mean (SD) 359 (159) 366 (157) 502** (224) 742 (309)*** 370 (108) 15.6, p < 0.001
 tTau > 470 pg/ml, n (%) 8 (16.0) 11 (24.4) 16 (45.7)** 15 (83.3)*** 1 (16.7) 31.9, p < 0.001
 pTau 181 (pg/ml), mean (SD) 51 (20) 51 (24) 67 (33)* 91 (43)*** 53 (16) 9.3, p < 0.001
 pTau 181 > 57 pg/ml, n (%) 15 (30.0) 14 (31.1) 20 (57.1)* 15 (83.3)*** 3 (50.0) 20.9, p < 0.001
 Aβ42/Tau ratio, Hulstaert formula, mean (SD) 1.36 (0.38) 1.15 (0.47)* 0.84 (0.49)*** 0.34 (0.14)*** 1.03 (0.63) 22.0, p < 0.001
 Abnormal Aβ42/Tau ratio, Hulstaert formula, n (%) 7 (14.0) 16 (35.6)** 23 (65.7)*** 18 (100)*** 2 (33.3) 46.7, p < 0.001
  1. Post-hoc unadjusted p value in comparison to the control group: *p < 0.05, **p < 0.01, ***p < 0.001
  2. Aβ42 beta-amyloid 42, AD Alzheimer’s disease, ADAScog 13 Alzheimer’s Disease Assessment Scale—cognitive part, APOE apolipoprotein E, CDR Clinical Dementia Rating, CDR-SOB Clinical Dementia Rating—sum of boxes, CO control group, CSF cerebrospinal fluid, FAQ Functional Activities Questionnaire, GDS Geriatric Depression Scale, MCI mild cognitive impairment, MMSE Mini-Mental -State Examination, n.s. not significant, SCD subjective cognitive decline, SD standard deviation